← Back to Search

Treatment for Lung Disease (DLP-LHC Trial)

N/A
Recruiting
Led By Meredith McCormack, MD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights

Summary

The goal of this observational study is to learn about lung structure and function in a group of 1000 healthy people aged 25 to 35. The main questions it aims to answer are whether people's bodies, environment, and general lung health are associated with: * the structure of the participants lungs' airways, * the structure of blood vessels in the participants lungs and heart, and * the participants lungs' ability to exchange gases. Participants will take four different lung function tests to measure lung function, including: * air movement in the lungs (oscillometry) * lung size (slow vital capacity (SVC) and functional residual capacity (FRC) * gas transfer in the lungs (diffusing capacity for carbon monoxide (DLCO).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Associations with airway-parenchymal dysanapsis
Associations with diffusing capacity for carbon monoxide (DLCO)
Associations with vascular parenchymal dysanapsis and cardiac chamber size

Find a Location

Who is running the clinical trial?

University of VermontOTHER
274 Previous Clinical Trials
3,742,756 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,889 Previous Clinical Trials
47,833,207 Total Patients Enrolled
Johns Hopkins UniversityLead Sponsor
2,307 Previous Clinical Trials
14,860,909 Total Patients Enrolled
~667 spots leftby Jul 2026